Navigation Links
Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
Date:11/6/2008

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an oral presentation covering the interim results of a U.S. Phase II trial investigating intravenous REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung is being delivered today by Dr. Monica Mita of the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas at the Chemotherapy Foundation Symposium XXVI, which is being held in New York from November 4-8, 2008.

"REOLYSIN(R) is a very well tolerated treatment that is also showing promising results in patients with metastatic sarcoma," said Dr. Mita. "We are pleased with the results and honored to present the data at major meetings."

To date, 35 patients have been enrolled in the study, and 29 are evaluable. 21% (6/29) of the evaluable patients experienced stable disease (SD) for more than 16 weeks. The investigators concluded that the study has met its established objectives, and that enrolment will continue to the full 52 patients.

-------------------------------------------------------------------------

Tumour Type Cycles Best Response

-------------------------------------------------------------------------

Synovial sarcoma 17* SD

-------------------------------------------------------------------------

Ewing's sarcoma 9* SD

-------------------------------------------------------------------------

Malignant Fibrous Histiocytoma 7* SD, tumor resection

after cycle 4

-------------------------------------------------------------------------

Leiomyosarcoma 6 SD

-------------------------------------------------------------------------

Chordoma 5* SD

-------------------------------------------------------------------------

Unspecified Spindle Cell 5* SD

-------------------------------------------------------------------------

* patients still on study

An oral presentation covering results of the trial (REO 014) is also scheduled to be delivered at the Connective Tissue Oncology Society (CTOS) annual meeting, being held in London, U.K. from November 13-15, 2008.

The slides will be available on the Oncolytics' website after the presentation.

Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research is also scheduled to present a poster at the CTOS meeting entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the Phase II trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
2. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
3. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
4. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
5. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
7. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
8. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
9. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
10. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ISELIN, New Jersey and ... 2016 Indegene ( ... kommerziellen und marketingorientierten Lösungen für die Life-Science-Branche, ... ), ein bekannter weltweiter Anbieter von innovativen ... im Zuge des Starts von IntraScience heute ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several ... Inc. at the City of Knowledge in Panama, a 6 year-old Duchenne’s ... the US earlier this year following FDA approval of a second application for ...
(Date:5/25/2016)... ... , ... Lajollacooks4u has become a rising hotspot for specialized team building events ... attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled ... , Each event kicks off with an olive oil and salt-tasting competition. From ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):